drugset / Trial / NCT00264550

An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00264550

Phase 3 Completed 444 enrolled Centocor, Inc. Schering-Plough · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate (MTX), as compared to methotrexate alone in rheumatoid arthritis (RA) patients who have active rheumatoid arthritis despite treatment with MTX.

Timeline

Start
2005-12
Primary completion
2007-09
Completion
2012-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Golimumab Monoclonal antibody 50 mg Subcutaneous
Subject Golimumab Monoclonal antibody 100 mg Subcutaneous
Subject Methotrexate Small molecule

Indications